ibrutinib,venetoclax,acalabrutinib
astrazeneca,abbvie,janssen,roche
['leusm', 'cll', 'venetoclax', ' ibru', 'thanks', 'acalabrutinib']
our national study characterizes a rare &amp; newly -defined disease, cll with prolymphocytic progression, inc. prognosis and response to targeted agents. thanks to tj rodgers for the mentorship! #ash22 #leusm 
Hematology/Oncology Fellow @DukeCancer | Cell Therapies, Stem Cell Transplant, Leukemia | Tweets ? med advice | Alum @NU_IntMed @UChiPritzker @Yale